917520--3/3/2009--INTEGRA_LIFESCIENCES_HOLDINGS

related topics

{product, liability, claim}

{property, intellectual, protect}

{customer, product, revenue}

{product, market, service}

{condition, economic, financial}

{personnel, key, retain}

{acquisition, growth, future}

{operation, international, foreign}

{control, financial, internal}

{cost, regulation, environmental}

{tax, income, asset}

{stock, price, share}

Our current strategy involves growth through acquisitions, which requires us to incur substantial costs and potential liabilities for which we may never realize the anticipated benefits. Our future financial results could be adversely affected by impairments or other charges. Current economic conditions may adversely affect the ability of hospitals, other customers, suppliers and distributors to access funds or otherwise have available liquidity, which could reduce orders for our products or interrupt our production or distribution. The disruption in the global financial markets and the economic downturn may adversely impact the availability and cost of credit. To market our products under development we will first need to obtain regulatory approval. Further, if we fail to comply with the extensive governmental regulations that affect our business, we could be subject to penalties and could be precluded from marketing our products. Certain of our products contain materials derived from animal sources and may become subject to additional regulation. Certain of our products are derived from human tissue and are subject to additional regulations and requirements. Lack of market acceptance for our products or market preference for technologies that compete with our products could reduce our revenues and profitability. Our intellectual property rights may not provide meaningful commercial protection for our products, potentially enabling third parties to use our technology or very similar technology and could reduce our ability to compete in the market. Our competitive position depends, in part, upon unpatented trade secrets which we may be unable to protect. Our success will depend partly on our ability to operate without infringing or misappropriating the proprietary rights of others. We may be involved in lawsuits relating to our intellectual property rights and promotional practices, which may be expensive. It may be difficult to replace some of our suppliers. If any of our manufacturing facilities were damaged and/or our manufacturing or business processes interrupted, we could experience lost revenues and our business could be seriously harmed. We are exposed to a variety of risks relating to our international sales and operations, including fluctuations in exchange rates, local economic conditions and delays in collection of accounts receivable. Changes in the healthcare industry may require us to decrease the selling price for our products, may reduce the size of the market for our products, or may eliminate a market, any of which could have a negative impact on our financial performance. Oversight of the medical device industry might affect the manner in which we may sell medical devices. Our private-label business depends significantly on key relationships with third parties, which we could be unable to establish and maintain. We may have significant product liability exposure and our insurance may not cover all potential claims. We are subject to requirements relating to hazardous materials which may impose significant compliance or other costs on us. The loss of key personnel could harm our business. We have had material weaknesses in our internal control over financial reporting and cannot assure you that additional material weaknesses will not be identified in the future. Access to the capital markets may be more expensive or subject to delays until such time as we qualify to file short-form registration statements.

Full 10-K form ▸

917520--3/3/2009--INTEGRA_LIFESCIENCES_HOLDINGS_CORP